Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0574 • ACR Convergence 2023
Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE
Kanwal Zahid Siddiqi¹, Amanda Hempel Zinglersen², Katrine Kjær Iversen¹ and Søren Jacobsen², ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases (COPEACT), Department of Rheumatology 4242, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark, ²Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Aberrant activation of type I IFN, and subsequent adverse clinical implications, have been widely discussed in relation to SLE. With the lack of consistent…
Abstract Number: 0592 • ACR Convergence 2023
Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Martin Aringer¹, Laurent Arnaud², Richard A. Furie³, Eric Morand⁴, Christine Peschken⁵, Barnabas Desta⁶, Eleni Rapsomaniki⁷, Jonatan Hedberg⁸, Tina Grünfeld Eén⁸, Alessandro Sorrentino⁹, Canna Ghia⁹, Stephanie Chen¹⁰ and Bo Ding⁸, ¹Faculty of Medicine TU Dresden, Dresden, Germany, ²University Hospitals of Strasbourg, Strasbourg, France, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease activity from June 2017 through November…
Abstract Number: 0731 • ACR Convergence 2023
ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus
Dai Dai¹, Shuangshuang Gu¹, Xiaxia Han¹, Huihua Ding², Yang Jiang¹, Sheng Chen¹ and Nan Shen², ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Age-associated B cells (ABCs) accumulate and contribute to the pathogenesis of systemic autoimmune diseases like lupus. Despite recent insights into the ontogeny and function…
Abstract Number: 0850 • ACR Convergence 2023
Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
Andrea Fava¹, Mohamed G. Atta¹, Jose Monroy-Trujillo², Derek Fine², Daniel Goldman³, Izmirly peter⁴, H Michael Belmont⁵, the Accelerating Medicines Partnership in RA/SLE⁶, Jill Buyon⁷ and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Multiple, Multiple, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…
Abstract Number: 0905 • ACR Convergence 2023
Low-Density Granulocytes and Neutrophil Extracellular Traps in Incomplete Systemic Lupus Erythematosus
Svenja Henning¹, Tobias Reimers², Berber Doornbos-van der Meer², Barbara Horvath³, Hendrika Bootsma⁴, Karina de Leeuw² and Johanna Westra², ¹University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen / Department of Dermatology, Groningen, Netherlands, ⁴Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Incomplete SLE (iSLE) defines a group of patients with symptoms typical of SLE but not meeting sufficient criteria required for the classification of SLE.…
Abstract Number: 0926 • ACR Convergence 2023
Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus
Aleksandra Bylinska, Miles Smith, Samantha Slight-Webb, Carla Guthridge, Caleb Marlin, Kevin Thomas, Christian Wright, Marci Beel, Susan Macwana, Wade DeJager, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Several groups of individuals are at higher risk for SLE, including those with African American ancestry (AA), lupus-associated autoantibodies (ANA+), or some clinical symptoms…
Abstract Number: 1212 • ACR Convergence 2023
Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, YONG EUN², COMFORT ANIM-KORANTENG² and AMANDA SAMMUT², ¹NYCHH- HARLEM, Bronx, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystemic immune-mediated disease with often nonspecific symptoms, associated with recurrent flares that can be life threatening. Prevalence…
Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Ekemini Ogbu¹, Hermine Brunner², Jennifer Huggins³, Angela Merritt³, Megan Quilan-Waters³, Catherine Robben³, Chen Chen³, Daniel J Lovell⁴ and Bin Huang³, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…
Abstract Number: 1448 • ACR Convergence 2023
Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients
Natalia Guajardo-Jauregui¹, Iris Colunga², José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Jesus Alberto Cardenas-De la Garza³ and Rosa Arvizu-Rivera⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that involves the deposition of immunocomplexes on vital organs, including the heart. Cardiovascular disease is…
Abstract Number: 1465 • ACR Convergence 2023
Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
Sarah Abi Doumeth¹, Marina Nighat Magrey² and Omer Pamuk³, ¹Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ²Case Western Reserve University, University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Previous studies have shown that the clinical manifestations of systemic lupus erythematosus (SLE) differ based on age of onset. Late onset SLE has been…
Abstract Number: 1482 • ACR Convergence 2023
Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan
Takehiro Nakai¹, Sho Fukui², Takahiro Asano¹, Futoshi Iwata¹, Hiroki Ozawa³, Satoshi Kawaai¹, Yukihiko Ikeda⁴, Haruyuki Yanaoka¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁵, Kenichi YAMAGUCHI⁶ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Brigham and Women's Hospital, Boston, MA, ³Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁴St Luke's international hospital in Japan, Tokyo, Japan, ⁵Kyorin University School of Medicine, Yokohoma, Japan, ⁶St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…
Abstract Number: 1499 • ACR Convergence 2023
Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study
Saira Sheikh¹, James Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio R. Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes García¹¹, IGNACIO GARCÍA-DE LA TORRE¹², Sofia Fernandes¹³, Julia HN Harris¹⁴, Abhishek Roy¹⁵, Jose Miyar Olaiz¹⁶, Paul WIlde¹⁷ and David A. Roth¹⁸, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Service of Rheumatology of the Internal Medicine Department, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Medical University of South Carolina, Charleston, SC, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central; Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Universidad de Guadalajara/Hospital General de Occidente, Guadalajara, Mexico, ¹³GlaxoSmithKline, Stevenage, United Kingdom, ¹⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Bangalore, India, ¹⁶GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Collegeville, PA
Background/Purpose: Belimumab (BEL) is an approved treatment for active SLE and LN, in addition to standard therapy (ST). Despite BEL clinical studies demonstrating a favorable…
Abstract Number: 1587 • ACR Convergence 2023
Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity
Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
Abstract Number: 1685 • ACR Convergence 2023
SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients
Zehra Kazmi¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²UT Heath San Antonio, Shavano Park, TX, ³UT Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: SLE patients have increased rates of HPV infection and cervical cancer. Although some factors are recognized for HPV infection in SLE, the relationship with…
Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].